These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 24522170

  • 1. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S, Dizdar OS, Oz Gul O, Guclu M, Unal OK, Tuncel E, Erturk E, Imamoglu S, Ersoy C.
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [Abstract] [Full Text] [Related]

  • 2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 3. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 4. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [Abstract] [Full Text] [Related]

  • 5. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 6. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [Abstract] [Full Text] [Related]

  • 7. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S, Facchinetti A, Bonora BM, Mariano V, Boscari F, Cipponeri E, Maran A, Avogaro A, Fadini GP, Bruttomesso D.
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [Abstract] [Full Text] [Related]

  • 8. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A, Wilhelm B, Kaiser M.
    MMW Fortschr Med; 2012 Dec 17; 154 Suppl 4():102-9. PubMed ID: 23326928
    [Abstract] [Full Text] [Related]

  • 9. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB.
    Diabetes Obes Metab; 2009 Jan 17; 11(1):69-71. PubMed ID: 19120433
    [Abstract] [Full Text] [Related]

  • 10. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group.
    Diabetes Obes Metab; 2009 Jan 17; 11(1):45-52. PubMed ID: 18643839
    [Abstract] [Full Text] [Related]

  • 11. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
    Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F.
    Diabetes Care; 2010 Jun 17; 33(6):1176-8. PubMed ID: 20200301
    [Abstract] [Full Text] [Related]

  • 12. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.
    Diabetologia; 2008 Mar 17; 51(3):408-16. PubMed ID: 18204830
    [Abstract] [Full Text] [Related]

  • 13. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC, EDITION 2 Study Investigators.
    Diabetes Care; 2014 Dec 17; 37(12):3235-43. PubMed ID: 25193531
    [Abstract] [Full Text] [Related]

  • 14. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM.
    Diabetes Care; 2013 Sep 17; 36(9):2536-42. PubMed ID: 23715753
    [Abstract] [Full Text] [Related]

  • 15. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
    Le Floch JP, Lévy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, Eschwege E, Fontaine P, Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group.
    Diabetes Care; 2009 Jan 17; 32(1):32-7. PubMed ID: 18945928
    [Abstract] [Full Text] [Related]

  • 16. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
    Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF, SOLVE Study Group.
    Diabetes Obes Metab; 2012 Dec 17; 14(12):1129-36. PubMed ID: 22830956
    [Abstract] [Full Text] [Related]

  • 17. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D, Nishimura R, Morimoto A, Tajima N, Utsunomiya K.
    Diabetes Technol Ther; 2012 Jul 17; 14(7):596-601. PubMed ID: 22775404
    [Abstract] [Full Text] [Related]

  • 18. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
    Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S.
    Diabet Med; 2010 Feb 17; 27(2):181-8. PubMed ID: 20546262
    [Abstract] [Full Text] [Related]

  • 19. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
    Rosenstock J, Rodbard HW, Bain SC, D'Alessio D, Seufert J, Thomsen AB, Svendsen CB, DeVries JH, Liraglutide-Detemir Study Group.
    J Diabetes Complications; 2013 Feb 17; 27(5):492-500. PubMed ID: 23746555
    [Abstract] [Full Text] [Related]

  • 20. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM.
    Clin Drug Investig; 2008 Feb 17; 28(11):697-701. PubMed ID: 18840012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.